imipramine

1
Reactions 1326 - 6 Nov 2010 Imipramine Hyperpigmentation in an elderly patient: case report An elderly woman developed hyperpigmentation during chronic treatment with imipramine for depression. The 66-year-old woman, who had been receiving imipramine daily for 40 years [dose and route not stated], presented with a 4- to 5-year history of progressive blue- brown discolouration of her neck, face and dorsal surface of her hands. The discolouration was noticeable soon after she began HRT, which was subsequently discontinued. Imipramine was maintained and the pigmentation worsened gradually, leading to social withdrawal. Examination revealed extensive macular blue-brown to purple hyperpigmentation involving her face, neck, upper chest and, to a lesser extent, her dorsal hands. A golden- brown pigment within tissue macrophages and the dermis was notable on biopsy, suggestive of medication-induced hyperpigmentation. The woman initially received a successful test spot laser treatment of the right preauricular skin with Q-switched alexandrite lasers. She subsequently received four treatments to her face and neck over a 6-month period, with marked clearing of the skin. Following her third treatment, several dark blue macules were evident along the temple and left jaw line, which resolved with ongoing treatment. She awaits similar treatment for her hand discolouration. Her mental status improved after resolution of the hyperpigmentation, with no recurrent episodes for 1 year. Further treatment will probably be required to maintain resolution, as she insists on continuing imipramine. Author comment: "Although the precise etiology of imipramine-induced hyperpigmentation is not known, drug metabolites are believed to deposit in the skin, possibly complexed with melanin. The obvious photodistribution of our patient’s hyperpigmentation supports the theory of photoactivation of the imipramine metabolites in producing the clinically apparent dyspigmentation." Orringer JS, et al. Treatment of imipramine-induced dyspigmentation with Q- switched alexandrite laser therapy. Dermatologic Surgery 36: 1469-1472, No. 9, Sep 2010. Available from: URL: http://dx.doi.org/10.1111/ j.1524-4725.2010.01662.x - USA 803043169 1 Reactions 6 Nov 2010 No. 1326 0114-9954/10/1326-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved

Upload: duongminh

Post on 19-Mar-2017

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Imipramine

Reactions 1326 - 6 Nov 2010

Imipramine

Hyperpigmentation in an elderly patient: casereport

An elderly woman developed hyperpigmentation duringchronic treatment with imipramine for depression.

The 66-year-old woman, who had been receivingimipramine daily for 40 years [dose and route not stated],presented with a 4- to 5-year history of progressive blue-brown discolouration of her neck, face and dorsal surfaceof her hands. The discolouration was noticeable soon aftershe began HRT, which was subsequently discontinued.Imipramine was maintained and the pigmentationworsened gradually, leading to social withdrawal.Examination revealed extensive macular blue-brown topurple hyperpigmentation involving her face, neck, upperchest and, to a lesser extent, her dorsal hands. A golden-brown pigment within tissue macrophages and the dermiswas notable on biopsy, suggestive of medication-inducedhyperpigmentation.

The woman initially received a successful test spot lasertreatment of the right preauricular skin with Q-switchedalexandrite lasers. She subsequently receivedfour treatments to her face and neck over a 6-monthperiod, with marked clearing of the skin. Following herthird treatment, several dark blue macules were evidentalong the temple and left jaw line, which resolved withongoing treatment. She awaits similar treatment for herhand discolouration. Her mental status improved afterresolution of the hyperpigmentation, with no recurrentepisodes for 1 year. Further treatment will probably berequired to maintain resolution, as she insists oncontinuing imipramine.

Author comment: "Although the precise etiology ofimipramine-induced hyperpigmentation is not known, drugmetabolites are believed to deposit in the skin, possiblycomplexed with melanin. The obvious photodistribution ofour patient’s hyperpigmentation supports the theory ofphotoactivation of the imipramine metabolites in producingthe clinically apparent dyspigmentation."Orringer JS, et al. Treatment of imipramine-induced dyspigmentation with Q-switched alexandrite laser therapy. Dermatologic Surgery 36: 1469-1472, No. 9,Sep 2010. Available from: URL: http://dx.doi.org/10.1111/j.1524-4725.2010.01662.x - USA 803043169

1

Reactions 6 Nov 2010 No. 13260114-9954/10/1326-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved